- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00081783
Xcellerated T CellsTM for Non-Hodgkin's Lymphoma (NHL) Patients
June 23, 2005 updated by: Xcyte Therapies
A Phase II Study of Xcellerated T CellsTM in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma (NHL)
This is a Phase II single arm study of a novel T cell immunotherapy in patients with indolent non-Hodgkin's lymphoma (NHL).
Eligible patients will have relapsed or refractory disease after receiving at least one and no more than four prior regimens.
Patients will receive Xcellerated T CellsTM, an ex vivo activated and expanded autologous T cell product, in an attempt to enhance immune responses with anti-tumor activity.
The primary endpoint of the study is to evaluate the efficacy of Xcellerated T Cells in patients with indolent NHL.
Secondary endpoints are to evaluate the safety of the therapy in this patient population, and to evaluate changes in the number and phenotype of T- and B-lymphocytes, as well as changes in the T cell receptor repertoire, hemoglobin levels, platelet counts and quantitative immunoglobulin levels.
In a subset of patients, fine-needle aspirates of malignant lymph nodes will be performed to assess changes in the lymphocyte composition and phenotype.
Bone marrow aspirates will be similarly evaluated.
Finally, anti-tumor immune responses will be evaluated in patients amenable to biopsy of enlarged lymph nodes.
Study Overview
Study Type
Interventional
Enrollment
40
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Greenbrae, California, United States, 94904
- Recruiting
- California Cancer Care
-
Contact:
- Jaime Chang
- Phone Number: 415-925-5040
- Email: JChang@cal-cancer-care.com
-
Principal Investigator:
- Jennifer B. Lucas, MD
-
Los Angeles, California, United States, 90033
- Not yet recruiting
- University of Southern California
-
Contact:
- Lynne Smith
- Phone Number: 323-865-0371
- Email: diansmi@usc.edu
-
Principal Investigator:
- Ann Mohrbacher, MD
-
San Diego, California, United States, 92123
- Recruiting
- Sharp Memorial Hospital
-
Principal Investigator:
- Charles Redfern, MD
-
Contact:
- Cathy Wood
- Phone Number: 858-939-5062
- Email: cathy.wood@sharp.com
-
San Diego, California, United States, 92093
- Recruiting
- University of California, San Diego
-
Contact:
- Vineeta Prasad
- Phone Number: 858-822-0337
- Email: vprasad@ucsd.edu
-
Principal Investigator:
- Januario E. Castro, MD
-
San Francisco, California, United States, 94143
- Recruiting
- University of California, San Francisco
-
Contact:
- Jenny Zhang
- Phone Number: 415-476-3741
- Email: jzhang@medicine.ucsf.edu
-
Principal Investigator:
- Lawrence D. Kaplan, MD
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Recruiting
- Rocky Mountain Cancer Centers
-
Contact:
- Juli Murphy, BS, CCRC
- Phone Number: 303-285-5087
- Email: juli.murphy@usoncology.com
-
Principal Investigator:
- Peter McSweeney, MD
-
-
Georgia
-
Roswell, Georgia, United States, 30342
- Recruiting
- Atlanta Cancer Care
-
Contact:
- Kathy Andrews
- Phone Number: 404-851-2359
- Email: kandrews@atlantacancercare.com
-
Principal Investigator:
- Ronald G. Steis, MD
-
-
Maryland
-
Baltimore, Maryland, United States, 21231
- Recruiting
- Johns Hopkins University
-
Contact:
- Susan Newton, RN
- Phone Number: 410-502-7985
- Email: meusesu@jhmi.edu
-
Principal Investigator:
- Ian W. Flinn, MD, PhD
-
Bethesda, Maryland, United States, 20817
- Recruiting
- Center for Cancer & Blood Disorders
-
Contact:
- Natalie Bongiorno, RN, BSN
- Phone Number: 301-571-0019
- Email: nbongiorno@ccbdmd.com
-
Principal Investigator:
- Ralph V. Boccia, MD
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Recruiting
- Dana-Farber Cancer Institute
-
Contact:
- Richard Boyajian
- Phone Number: 42314 617-632-3352
- Email: Richard_Boyajian@dfci.harvard.edu
-
Principal Investigator:
- Arnold Freedman, MD
-
-
Missouri
-
St. Louis, Missouri, United States, 63110
- Recruiting
- Washington University
-
Contact:
- Kelly Bryan
- Phone Number: 314-362-6359
- Email: kbryan@im.wustl.edu
-
Principal Investigator:
- Nancy L. Bartlett, MD
-
-
New Jersey
-
New Brunswick, New Jersey, United States, 08903
- Recruiting
- Cancer Institute of New Jersey
-
Contact:
- John Martin
- Phone Number: 732-235-8995
- Email: martinj4@umdnj.edu
-
Principal Investigator:
- Roger K. Strair, MD, PhD
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Recruiting
- Ohio State University
-
Contact:
- Mary Weiss
- Phone Number: 614-293-3437
- Email: Weiss-3@medctr.osu.edu
-
Principal Investigator:
- Thomas Lin, MD
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Recruiting
- Oregon Health Sciences University
-
Contact:
- Aubyn Grant, CCRP
- Phone Number: 503-494-5074
- Email: granta@ohsu.edu
-
Principal Investigator:
- Brandon Hayes-Lattin, MD
-
-
South Carolina
-
Greenville, South Carolina, United States, 29605
- Recruiting
- Cancer Centers of the Carolinas
-
Contact:
- Kim Williams, RN
- Phone Number: 864-241-6251
- Email: kimberly.williams@usoncology.com
-
Principal Investigator:
- Joe J. Stephenson, MD
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- MD Anderson Cancer Center
-
Contact:
- Ana Ayala
- Phone Number: 713-792-3610
- Email: abayala@mdanderson.org
-
Principal Investigator:
- Peter W. McLaughlin, MD
-
-
Washington
-
Seattle, Washington, United States, 98104
- Recruiting
- Swedish Cancer Institute
-
Contact:
- Toni Oien, CCRC
- Phone Number: 206-386-2831
- Email: toni.oien@swedish.org
-
Principal Investigator:
- Michael S. Milder, MD
-
Seattle, Washington, United States, 98111
- Recruiting
- Virginia Mason
-
Contact:
- Aimee Perrault-Gray
- Phone Number: 61870 206-583-6559
- Email: Aimee.PerraultGray@vmmc.org
-
Principal Investigator:
- David M. Aboulafia, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Indolent non-Hodgkin's Lymphoma (NHL), with one of the following subtypes according to the REAL Classification: follicular lymphoma, small lymphocytic lymphoma (SLL), extranodal marginal zone B-cell lymphoma (MALT), nodal marginal zone B-cell lymphoma (monocytoid B-cell lymphoma), splenic marginal zone lymphoma (splenic lymphoma with villous lymphocytes) and mantle cell lymphoma. Other subtypes require approval of the Medical Monitor. At least 16 patients with small lymphocytic lymphoma, and no more than eight patients with mantle cell lymphoma will be enrolled.
- Stage III or IV disease at any time in the past
- Relapsed or refractory disease following most recent treatment. Patients are considered to have refractory disease if their last treatment course did not result in a complete or partial response, or if time to disease progression was six months or less. Patients are considered to have relapsed disease if time to disease progression is more than six months. Patients who have achieved a partial or complete response following most recent therapy must have demonstrated progressive disease.
- Patients must have received at least one prior course of systemic therapy for NHL and no more than four prior courses of therapy. Repeat courses of the same therapeutic regimen separated in time by six or more months are considered separate treatment courses, with the exception of single-agent rituximab. Patients with more than four prior courses of therapy may be enrolled at the discretion of the Medical Monitor after discussion with the Investigator.
- Radiographically bi-dimensionally measurable disease. Imaging need not be performed within 15 days prior to registration. Prior scans are acceptable provided that there has been no intervening therapy for NHL. Scans will be obtained at baseline, following registration.
- Age of at least 18 years
- ECOG performance status of 0 to 2
- White blood count (WBC) ≥ 3,000/mm3, absolute neutrophil count (ANC) ≥ 1000/mm3
- CD3+ > 1% of total peripheral white blood cell count by flow cytometry
- Platelet count > 50,000/mm3
- Hemoglobin ³ 10.0 g/dL. Transfusion with red blood cells or use of erythropoietin is permissible.
- Serum total bilirubin and alanine aminotransferase (ALT) ≤ 2.0 times the upper limit of normal
- Serum creatinine ≤ 2.0 mg/dL
- Serum human anti-mouse antibody (HAMA) titer undetectable or within the normal range, and no history of symptomatic allergic reactions to mice or murine (mouse) proteins. Patients with elevated HAMA levels may be enrolled at the discretion of the Medical Monitor after discussion with the Investigator.
- Negative test results for current/active infection with HIV-1, HIV-2, HTLV-1, HTLV-2, hepatitis B and hepatitis C within 30 days of registration. (Antibody, antigen and nucleic acid tests acceptable, depending on institutional standards)
- Women of childbearing potential must have a negative serum pregnancy test. Both men and women agree to use a medically accepted form of contraception from the time of initial screening through completion of the study.
- Able to comprehend and provide signed informed consent
Exclusion Criteria:
- Evidence of Hodgkin's lymphoma, Burkitt's lymphoma, diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, lymphoplasmacytic lymphoma, hairy cell leukemia, primary central nervous system lymphoma or any other aggressive lymphoma
- Any T cell lymphoma
- Evidence of primary cutaneous anaplastic large cell lymphoma, Richter's Syndrome, large granular lymphocytosis and Sézary-cell leukemia. Patients with a prior diagnosis of chronic lymphocytic leukemia, as evidenced by absolute peripheral lymphocyte count of greater than 5,000 per mm3 at any time in the past, are not eligible.
- Leukemic manifestations of non-Hodgkin's lymphoma. Small lymphocytic lymphoma patients with peripheral lymphocyte count greater than 5,000 per mm3
- Receipt of any chemotherapy, monoclonal antibody, investigational or other systemic therapy (except glucocorticoids as noted below) for the treatment of NHL within 2 months prior to registration
- Receipt of glucocorticoids (with the exception of inhaled glucocorticoids) within 1 month prior to registration
- Receipt of intravenous immunoglobulin (IVIG) within 1 month of registration
- Registration for, or plans to participate in, any other clinical trial of an investigational agent concurrently with this trial
- History of malignancy other than NHL within five years of registration, except adequately treated basal or squamous cell skin cancer or in situ carcinoma of the cervix. Other exceptions must be approved by the Xcyte Therapies' Medical Monitor prior to registration.
- Infection requiring treatment with antibiotics, antifungal, or antiviral agents within seven days of registration
- Active autoimmune disease requiring systemic treatment
- Major organ system dysfunction including (but not limited to): New York Heart Association Class III or IV, severe pulmonary, renal, hepatic, gastrointestinal, neurologic or psychiatric dysfunction which would impair patient's ability to participate in the trial
- Any other pertinent medical or psychological condition which leads the Investigator to believe the study would not be appropriate treatment or in the patient's best interest
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Mark W. Frohlich, MD, Xcyte Therapies
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2004
Study Registration Dates
First Submitted
April 20, 2004
First Submitted That Met QC Criteria
April 21, 2004
First Posted (Estimate)
April 22, 2004
Study Record Updates
Last Update Posted (Estimate)
June 24, 2005
Last Update Submitted That Met QC Criteria
June 23, 2005
Last Verified
March 1, 2005
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- XT009
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Hodgkin's Lymphoma
-
Memorial Sloan Kettering Cancer CenterRecruitingNon-Hodgkin Lymphoma | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryUnited States
-
Immune DesignMerck Sharp & Dohme LLCTerminatedFollicular Low Grade Non-Hodgkin's Lymphoma
-
PrECOG, LLC.Genentech, Inc.CompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma Follicular | Non-Hodgkin's Lymphoma, Adult High GradeUnited States
-
University Health Network, TorontoCompletedHodgkin's Lymphoma | Non Hodgkin's LymphomaCanada
-
Hoffmann-La RocheCompletedDiffuse Large B-Cell Lymphoma, Non-Hodgkin's LymphomaHong Kong, Germany, Philippines, Taiwan, Turkey, Canada, Australia, Austria, New Zealand, Thailand, Hungary, Italy, Korea, Republic of, Romania, Netherlands, Brazil, Indonesia, Croatia, Egypt, Portugal, Sweden, Colombia, Argentina, De... and more
-
SCRI Development Innovations, LLCBiogenCompleted
-
Auxilio Mutuo Cancer CenterCompletedRefractory Aggressive Non-Hodgkin's Lymphoma | Relapsing Aggressive Non-Hodgkin's Lymphoma
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Not yet recruitingLymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
-
Chinese PLA General HospitalRecruiting
-
Hebei Senlang Biotechnology Inc., Ltd.RecruitingNon-hodgkin's LymphomaChina
Clinical Trials on Xcellerated T Cells
-
Xcyte TherapiesCompleted
-
Everett MeyerNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...CompletedLymphoma, Non-Hodgkin | Acute Myeloid Leukemia | Acute Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Myelodysplastic Syndromes (MDS) | Acute Lymphoblastic Leukemia (ALL) | Myeloid Leukemia, Chronic | Myeloproliferative SyndromeUnited States
-
Sorrento Therapeutics, Inc.WithdrawnBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreas Cancer | Peritoneal Carcinomatosis | Peritoneal Metastases | Carcinoembryonic AntigenUnited States
-
First Affiliated Hospital Xi'an Jiaotong UniversityEureka Therapeutics Inc.Unknown
-
Southwest Hospital, ChinaUnknownLymphoma, Large B-Cell, DiffuseChina
-
Wuhan Sian Medical Technology Co., LtdWuhan Union Hospital, China; Xiangyang Central Hospital; Jingzhou Central Hospital and other collaboratorsUnknownB Cell Lymphoma | Acute Lymphoblastic LeukemiaChina
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinCompletedLymphoma, B-Cell | Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingMultiple Myeloma | New Diagnosis TumorChina
-
Peking University People's HospitalNot yet recruitingT-cell Non-Hodgkin's Lymphoma